What the published research says — and doesn't yet say — about how Muse cells find their way to damaged tissue.
Since their initial characterization by Dr. Mari Dezawa's group, Muse cells have been studied for a distinctive behavior after systemic administration: a tendency to migrate preferentially toward damaged or inflamed tissue rather than distributing uniformly throughout the body. Published research has proposed that this migration is mediated, at least in part, by the interaction between sphingosine-1-phosphate (S1P) — which increases locally at sites of tissue injury — and S1PR2, an S1P receptor subtype expressed on Muse cells. See What Is S1P? and What Is S1PR2?.
If Muse cells reliably home to injury sites via this mechanism, it would offer a rationale for systemic (intravenous) administration in conditions where the injury site isn't easily accessible for direct injection — the cells would, in principle, be guided toward the area of damage rather than requiring precise local delivery.
This is an area of active, ongoing research rather than settled clinical fact. Findings on homing behavior come primarily from specific experimental injury models, and the degree to which they generalize across tissue types, injury types, and delivery methods is still being characterized. Homing research is useful as mechanistic background for understanding why a route of administration might be chosen — it is not, by itself, evidence of clinical efficacy for any specific product or indication.
This page is educational reference material for licensed healthcare providers and does not constitute medical, legal, or regulatory advice. HCT/P products are not FDA-approved.